Biologic disease-modifying anti-rheumatic drugs (bDMARDs), with TNF inhibitors (TNFi) mostly used, have dramatically improved the prognosis in JIA [23], but treatment-resistant disease, disease flares, and subclinical inflammation are still a problem for many children [24, 25]. Here, TNF is linked to juvenile idiopathic arthritis.